|1.||Nakahara, Tsutomu: 2 articles (02/2013 - 01/2010)|
|2.||Nagamitsu, Tohru: 2 articles (02/2013 - 01/2010)|
|3.||Ishii, Kunio: 2 articles (02/2013 - 01/2010)|
|4.||Ozaki, Hiromi: 2 articles (02/2013 - 01/2010)|
|5.||Abe, Naomichi: 2 articles (02/2013 - 01/2010)|
|6.||Wada, Yoshiko: 2 articles (02/2013 - 01/2010)|
|7.||Nakamura, Kazuhide: 2 articles (01/2006 - 12/2004)|
|8.||Takahashi, Kazumi: 2 articles (01/2006 - 12/2004)|
|9.||Yamamoto, Atsushi: 2 articles (01/2006 - 12/2004)|
|10.||Taguchi, Eri: 2 articles (01/2006 - 12/2004)|
12/01/2004 - "The propagation of various cancer cell lines in vitro was not inhibited by KRN633. "
01/01/2006 - "The solid dispersion form of KRN633 also dramatically inhibited human tumor growth in murine and rat xenograft models: similar rates of tumor growth inhibition were obtained with 10- to 25-fold lower doses of the solid dispersion preparation relative to the pure drug in its crystalline state. "
12/01/2004 - "Histologic analysis of tumor xenografts treated with KRN633 revealed a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability. "
12/01/2004 - "KRN633 also caused the regression of some well-established tumors and those that had regrown after the cessation of treatment. "
12/01/2004 - "administration of KRN633 inhibited tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. "
|3.||Weight Loss (Weight Reduction)
01/01/2006 - "In addition, a dose-finding study using the solid dispersion form in a rat xenograft model revealed that there was a substantial range of doses at which KRN633 in the solid dispersion form showed significant antitumor activity but did not induce weight loss or elevate total urinary protein levels. "
|4.||Premature Birth (Birth, Premature)
01/01/2011 - "Effects of enzastaurin and KRN633 on phosphorylation status of key signaling molecules and viability of the mesothelioma cells were determined. "
01/01/2011 - "To examine the role of both protein kinase C (PKC)-β and vascular endothelial growth factor receptor (VEGFR)-2 in malignant pleural mesothelioma (MPM) using respective inhibitors, enzastaurin and KRN633. "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|4.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|5.||Protein Kinase C
|7.||SU 5416 (SU5416)
|1.||Heterologous Transplantation (Xenotransplantation)